Correction to “Treating Hematological Malignancies With
                    OR
                    ‐2100, an Orally Bioavailable Prodrug of Decitabine”

doi:10.1111/cas.70230

journal article Open Access Oct 20, 2025

Correction to “Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine”

Cancer Science Vol. 117 No. 1 pp. 281-281 · Wiley

View at Publisher Save 10.1111/cas.70230

Topics

No keywords indexed for this article. Browse by subject →

Metrics

0

Citations

0

References

Details

Published: Oct 20, 2025
Vol/Issue: 117(1)
Pages: 281-281
License: View

Cite This Article

(2025). Correction to “Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine”. Cancer Science, 117(1), 281-281. https://doi.org/10.1111/cas.70230

Correction to “Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine”

You May Also Like